Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia
YANG Wen-Yu, CHEN Xiao-Juan, WANG Shu-Chun, GUO Ye, LIU Tian-Feng, CHANG Li-Xian, LIU Fang, ZHU Xiao-Fan
Diagnostic and Therapeutic Center of Children's Blood Disease, Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin 300020, China
Abstract Objective To study gene mutations and clinical features in children with juvenile myelomonocytic leukemia (JMML). Methods The clinical data of 14 children who were diagnosed with JMML and were examined for the detection of common gene mutations were retrospectively analyzed. Results Eleven (79%) out of 14 cases were male, and 3 (21%) were female. The median age at diagnosis was 2.0 years (age range: 0.6-6.0 years). Among 14 cases, there were 4 cases (29%) with PTPN11 mutation, 3 cases (21%) with N-RAS mutation, 1 case (7%) with PTPN11 mutation and K-RAS mutation, and 6 cases (43%) without any mutation. All four cases in the PTPN11 mutation group were male, and their median age was 2.5 years; interval from onset to diagnosis was 1.0 month; the white blood cell (WBC) count and absolute monocytes in peripheral blood were significantly higher, while the platelet (PLT) count was lower, as compared with the other three groups; they were followed up, and 3 cases died and 1 case had a progressive disease. In the N-RAS mutation group, there were two male cases and one female case, and their median age was 2.0 years; interval from onset to diagnosis was 13.7 months; after follow-up, 2 cases died and 1 case did not have an obviously progressive disease. Conclusions PTPN11 mutation is the most common mutation in JMML. The cases with PTPN11 mutation often have higher WBC count and absolute monocytes in peripheral blood, a lower PLT count, and a rapid disease progression, and their clinical outcomes are poor. The cases with N-RAS mutation have a slow disease progression. The clinical characteristics of the patients with compound mutations are not sure because of the small number of cases, and further clinical observation is indispensable.
YANG Wen-Yu,CHEN Xiao-Juan,WANG Shu-Chun et al. Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia[J]. CJCP, 2015, 17(1): 1-5.
YANG Wen-Yu,CHEN Xiao-Juan,WANG Shu-Chun et al. Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia[J]. CJCP, 2015, 17(1): 1-5.
Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options[J]. Br J Haematol, 2008, 140(6): 610-624.
[2]
Loh ML. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia[J]. Hematology Am Soc Hematol Educ Program, 2010, 2010: 357-362.
[3]
Liu X, Sabnis H, Bunting KD, et al. Molecular targets for the treatment of juvenile myelomonocytic leukemia[J]. Adv Hematol, 2012, 2012: 308252.
[4]
Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia[J]. Br J Haematol, 2011, 152(6): 677-687.
[5]
Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors[J]. Blood, 1991, 77(5): 925-929.
[6]
Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia[J]. Blood, 2009, 114(9): 1859-1863.
[7]
Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis[J]. Blood, 2004, 103(6): 2325-2331.
[8]
Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia[J]. Nat Genet, 2003, 34(2): 148-150.
[9]
Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease[J]. Blood, 2005, 106(6): 2183-2185.
[10]
Schubbert S, Lieuw K, Rowe SL, et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells[J]. Blood, 2005, 106(1): 311-317.
[11]
Chan RJ, Leedy MB, Munugalavadla V, et al. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor[J]. Blood, 2005, 105(9): 3737-3742.
[12]
Matsuda K, Shimada A, Yoshida N, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations[J]. Blood, 2007, 109(12): 5477-5480.
[13]
Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)[J]. Leukemia, 1999, 13(1): 32-37.
[14]
Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)[J]. Blood, 1997, 89(10): 3534-3543.
[15]
Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival[J]. Br J Haematol, 2003, 121(5): 758-767.
[16]
Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOGMDS/EBMT trial[J]. Blood, 2005, 105(1): 410-419.
